Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Jon C. Ogg | Jul 10, 2015 at 12:35 PM EDT

Biogen Loses Its Head of Research and Development

Biogen announced on Friday that it is losing its head of research and development at the end of July.

Lee Jackson | Jul 10, 2015 at 8:35 AM EDT

4 Specialty Pharmaceutical Stocks Could Be the Next Takeover Candidates

While there is absolutely no guarantee that any of these companies catch a bid and be bought out, they all…

Douglas A. McIntyre | Jul 9, 2015 at 6:40 AM EDT

Taxing Tobacco to Reduce Smoking

If the World Health Organization (WHO) has its way, increases in national tobacco taxes may curtail tobacco use around the…

Chris Lange | Jul 8, 2015 at 4:12 PM EDT

Meet the Next Mega Blockbuster Heart Drug

Novartis is getting ready to steal a lot of hearts with its newest drug. The FDA has approved Entresto tablets…

Lee Jackson | Jul 8, 2015 at 8:55 AM EDT

3 UBS Must-Own Large-Cap Pharmaceutical Stocks

A new report from UBS highlights three stocks that the firm likes best now. Not only do they all pay…

Chris Lange | Jul 8, 2015 at 8:45 AM EDT

Gensight Biologics Files for Initial Public Offering

Gensight Biologics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).

Jon C. Ogg | Jul 7, 2015 at 1:25 PM EDT

What FDA Breakthrough Therapy Designation Means for Dyax

Dyax announced on Tuesday that the FDA has granted a key breakthrough therapy designation for the investigation of DX-2930 for…

Chris Lange | Jul 7, 2015 at 11:25 AM EDT

Horizon Pharma Makes Hostile Bid to Acquire DepoMed

Horizon Pharma has gone hostile in its attempt to take over DepoMed. These companies have been in talks since March,…

Chris Lange | Jul 7, 2015 at 7:35 AM EDT

5 Big Upcoming FDA Decisions Expected in July

24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of July and…

Chris Lange | Jul 6, 2015 at 3:10 PM EDT

Big Downside Ahead for Raptor?

ThinkstockRaptor Pharmaceuticals Corp. (NASDAQ: RPTP) was downgraded by Oppenheimer to an Underperform rating from Perform with an $8 price target,…

Chris Lange | Jul 6, 2015 at 1:45 PM EDT

Is Gilead Headed Lower From Here?

Merrill Lynch recently updated its view on Gilead Sciences, maintaining its Underperform rating for the stock but raising its price…

Chris Lange | Jul 6, 2015 at 10:45 AM EDT

Health Insurance Mergers Falling Into Place

Over the long weekend, the first move toward an acquisition was made in the health insurance industry.

Paul Ausick | Jul 1, 2015 at 1:10 PM EDT

Implant Maker ConforMIS Jumps a Third on IPO

ConforMIS shares began trading Wednesday morning at $18 and popped to a high of $20.42 before pulling back.

Chris Lange | Jul 1, 2015 at 12:05 PM EDT

IPO of Zynerba Pharmaceuticals Targets Cannabinoid Therapeutics

Zynerba Pharmaceuticals has filed with the U.S. Securities and Exchange Commission for its initial public offering (IPO).

Chris Lange | Jul 1, 2015 at 11:20 AM EDT

Atara Biotherapeutics Files for IPO

Atara Biotherapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).

1 … 257 258 259 260 261 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Biogen Loses Its Head of Research and Development

4 Specialty Pharmaceutical Stocks Could Be the Next Takeover Candidates

Taxing Tobacco to Reduce Smoking

Meet the Next Mega Blockbuster Heart Drug

3 UBS Must-Own Large-Cap Pharmaceutical Stocks

Gensight Biologics Files for Initial Public Offering

What FDA Breakthrough Therapy Designation Means for Dyax

Horizon Pharma Makes Hostile Bid to Acquire DepoMed

5 Big Upcoming FDA Decisions Expected in July

Big Downside Ahead for Raptor?

Is Gilead Headed Lower From Here?

Health Insurance Mergers Falling Into Place

Implant Maker ConforMIS Jumps a Third on IPO

IPO of Zynerba Pharmaceuticals Targets Cannabinoid Therapeutics

Atara Biotherapeutics Files for IPO

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Health and Healthcare Articles

All Health and Healthcare Articles

Biogen Loses Its Head of Research and Development

4 Specialty Pharmaceutical Stocks Could Be the Next Takeover Candidates

Taxing Tobacco to Reduce Smoking

Meet the Next Mega Blockbuster Heart Drug

3 UBS Must-Own Large-Cap Pharmaceutical Stocks

Gensight Biologics Files for Initial Public Offering

What FDA Breakthrough Therapy Designation Means for Dyax

Horizon Pharma Makes Hostile Bid to Acquire DepoMed

5 Big Upcoming FDA Decisions Expected in July

Big Downside Ahead for Raptor?

Is Gilead Headed Lower From Here?

Health Insurance Mergers Falling Into Place

Implant Maker ConforMIS Jumps a Third on IPO

IPO of Zynerba Pharmaceuticals Targets Cannabinoid Therapeutics

Atara Biotherapeutics Files for IPO

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how